Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Phase 2, Single Arm, Two Cohort Study Evaluating the Efficacy, Safety, and Pharmacokinetics of AMG337 in Subjects With MET Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma or Other MET Amplified Solid Tumors

NCT02016534 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT02016534
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02016534 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Phase 2, Single Arm, Two Cohort Study Evaluating the Efficacy, Safety, and Pharmacokinetics of AMG337 in Subjects With MET Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma or Other MET Amplified Solid Tumors
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Terminated
Start date
February 28, 2014
Completion date
October 31, 2016
Enrollment
60 (actual)
Sites
97

Conditions

As the registry lists them; a condition with its own page is linked.

stomach neoplasms